OKYO Pharma (OKYO) Competitors

$1.60 +0.01 (+0.31%)

As of 03:34 PM Eastern

OKYO vs. CHRS, HELP, ARTV, NERV, and FHTX

Should you buy OKYO Pharma stock or one of its competitors? MarketBeat compares OKYO Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OKYO Pharma include Coherus Oncology (CHRS), Cybin (HELP), Artiva Biotherapeutics (ARTV), Minerva Neurosciences (NERV), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry.

How does OKYO Pharma compare to Coherus Oncology?

OKYO Pharma (NASDAQ:OKYO) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Coherus Oncology has higher revenue and earnings than OKYO Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Coherus Oncology	$46.88M	4.85	$168.02M	$1.67	0.88

OKYO Pharma has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

In the previous week, Coherus Oncology had 3 more articles in the media than OKYO Pharma. MarketBeat recorded 6 mentions for Coherus Oncology and 3 mentions for OKYO Pharma. Coherus Oncology's average media sentiment score of 0.45 beat OKYO Pharma's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OKYO Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coherus Oncology	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Coherus Oncology has a net margin of 397.30% compared to OKYO Pharma's net margin of 0.00%. OKYO Pharma's return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Coherus Oncology	397.30%	-198.90%	-46.65%

OKYO Pharma currently has a consensus target price of $6.33, indicating a potential upside of 297.07%. Coherus Oncology has a consensus target price of $8.67, indicating a potential upside of 487.57%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Coherus Oncology beats OKYO Pharma on 9 of the 12 factors compared between the two stocks.

How does OKYO Pharma compare to Cybin?

OKYO Pharma (NASDAQ:OKYO) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

OKYO Pharma has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market. Comparatively, Cybin has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

OKYO Pharma presently has a consensus target price of $6.33, suggesting a potential upside of 297.07%. Cybin has a consensus target price of $58.75, suggesting a potential upside of 1,292.18%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A

In the previous week, OKYO Pharma had 3 more articles in the media than Cybin. MarketBeat recorded 3 mentions for OKYO Pharma and 0 mentions for Cybin. Cybin's average media sentiment score of 1.89 beat OKYO Pharma's score of 0.00 indicating that Cybin is being referred to more favorably in the news media.

Company	Overall Sentiment
OKYO Pharma	Neutral
Cybin	Very Positive

OKYO Pharma's return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Cybin	N/A	-59.98%	-50.80%

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cybin beats OKYO Pharma on 6 of the 11 factors compared between the two stocks.

How does OKYO Pharma compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, Artiva Biotherapeutics had 5 more articles in the media than OKYO Pharma. MarketBeat recorded 8 mentions for Artiva Biotherapeutics and 3 mentions for OKYO Pharma. Artiva Biotherapeutics' average media sentiment score of 0.55 beat OKYO Pharma's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OKYO Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.0% of OKYO Pharma shares are held by institutional investors. 21.4% of Artiva Biotherapeutics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Artiva Biotherapeutics currently has a consensus target price of $39.00, suggesting a potential upside of 357.10%. OKYO Pharma has a consensus target price of $6.33, suggesting a potential upside of 297.07%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Artiva Biotherapeutics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

OKYO Pharma's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
OKYO Pharma	N/A	N/A	N/A

Artiva Biotherapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

OKYO Pharma has lower revenue, but higher earnings than Artiva Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	843.64	-$83.86M	-$3.54	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

Summary

Artiva Biotherapeutics beats OKYO Pharma on 8 of the 13 factors compared between the two stocks.

How does OKYO Pharma compare to Minerva Neurosciences?

OKYO Pharma (NASDAQ:OKYO) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

OKYO Pharma has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Minerva Neurosciences	N/A	N/A	-32.63%

OKYO Pharma currently has a consensus target price of $6.33, suggesting a potential upside of 297.07%. Minerva Neurosciences has a consensus target price of $10.50, suggesting a potential upside of 141.38%. Given OKYO Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe OKYO Pharma is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

In the previous week, OKYO Pharma had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for OKYO Pharma and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.34 beat OKYO Pharma's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OKYO Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Comparatively, 10.4% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

OKYO Pharma beats Minerva Neurosciences on 8 of the 10 factors compared between the two stocks.

How does OKYO Pharma compare to Foghorn Therapeutics?

OKYO Pharma (NASDAQ:OKYO) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

OKYO Pharma has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Foghorn Therapeutics	-266.88%	N/A	-35.38%

OKYO Pharma has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.97, indicating that its share price is 197% more volatile than the broader market.

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

OKYO Pharma has higher earnings, but lower revenue than Foghorn Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Foghorn Therapeutics	$30.91M	6.89	-$74.28M	-$1.16	N/A

In the previous week, OKYO Pharma had 2 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for OKYO Pharma and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.78 beat OKYO Pharma's score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OKYO Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OKYO Pharma presently has a consensus price target of $6.33, suggesting a potential upside of 297.07%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 214.84%. Given OKYO Pharma's higher possible upside, analysts clearly believe OKYO Pharma is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Foghorn Therapeutics beats OKYO Pharma on 7 of the 13 factors compared between the two stocks.

Get OKYO Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKYO vs. The Competition

Export

Metric	OKYO Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$64.69M	$3.26B	$6.27B	$12.13B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	N/A	18.70	20.61	25.11
Price / Sales	N/A	281.88	578.26	91.48
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	-9.97	6.59	9.72	6.63
Net Income	-$4.71M	$24.30M	$3.55B	$335.73M
7 Day Performance	-1.54%	-3.36%	-1.89%	-1.80%
1 Month Performance	-3.92%	-7.67%	-3.77%	-1.69%
1 Year Performance	-0.13%	52.30%	29.58%	27.59%

OKYO Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKYO OKYO Pharma	1.7221 of 5 stars	$1.60 +0.3%	$6.33 +297.1%	+7.4%	$64.69M	N/A	N/A	7	News Coverage
CHRS Coherus Oncology	3.154 of 5 stars	$1.71 -12.3%	$8.67 +406.8%	+95.8%	$263.71M	$46.88M	1.02	330	Gap Down High Trading Volume
HELP Cybin	3.8892 of 5 stars	$5.06 -0.8%	$58.75 +1,061.1%	N/A	$263.32M	N/A	N/A	50	Positive News
ARTV Artiva Biotherapeutics	4.0466 of 5 stars	$10.63 +0.3%	$39.00 +266.9%	+354.2%	$262M	$250K	N/A	81	Analyst Downgrade
NERV Minerva Neurosciences	2.1114 of 5 stars	$5.60 -0.5%	$10.50 +87.5%	+216.0%	$260.90M	N/A	N/A	9	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKYO) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OKYO Pharma (OKYO) Competitors

OKYO vs. CHRS, HELP, ARTV, NERV, and FHTX

How does OKYO Pharma compare to Coherus Oncology?

Summary

How does OKYO Pharma compare to Cybin?

Summary

How does OKYO Pharma compare to Artiva Biotherapeutics?

Summary

How does OKYO Pharma compare to Minerva Neurosciences?

Summary

How does OKYO Pharma compare to Foghorn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OKYO Pharma (OKYO) Competitors

OKYO vs. CHRS, HELP, ARTV, NERV, and FHTX

How does OKYO Pharma compare to Coherus Oncology?

Which has stronger earnings and valuation, OKYO or CHRS?

Which has more risk and volatility, OKYO or CHRS?

Does the media favor OKYO or CHRS?

Do insiders & institutionals hold more shares of OKYO or CHRS?

Is OKYO or CHRS more profitable?

Do analysts rate OKYO or CHRS?

Summary

How does OKYO Pharma compare to Cybin?

Which has more risk & volatility, OKYO or HELP?

Do analysts recommend OKYO or HELP?

Which has preferable earnings and valuation, OKYO or HELP?

Does the media favor OKYO or HELP?

Is OKYO or HELP more profitable?

Do institutionals & insiders hold more shares of OKYO or HELP?

Summary

How does OKYO Pharma compare to Artiva Biotherapeutics?

Does the media prefer ARTV or OKYO?

Do insiders & institutionals have more ownership in ARTV or OKYO?

Do analysts recommend ARTV or OKYO?

Is ARTV or OKYO more profitable?

Which has more risk & volatility, ARTV or OKYO?

Which has stronger valuation & earnings, ARTV or OKYO?

Summary

How does OKYO Pharma compare to Minerva Neurosciences?

Which has more volatility & risk, OKYO or NERV?

Is OKYO or NERV more profitable?

Do analysts recommend OKYO or NERV?

Which has stronger valuation and earnings, OKYO or NERV?

Does the media favor OKYO or NERV?

Do institutionals and insiders have more ownership in OKYO or NERV?

Summary

How does OKYO Pharma compare to Foghorn Therapeutics?

Is OKYO or FHTX more profitable?

Which has more volatility and risk, OKYO or FHTX?

Do insiders and institutionals have more ownership in OKYO or FHTX?

Which has preferable earnings and valuation, OKYO or FHTX?

Does the media favor OKYO or FHTX?

Do analysts recommend OKYO or FHTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools